Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B

INTRODUCTION: In 2010, nonacog alfa became the first recombinant factor IX (rFIX) available in Japan for patients with haemophilia B. AIM: To determine real‐world safety (adverse events, incidence of inhibitors) and effectiveness of nonacog alfa in Japan. METHODS: This multicentre, prospective, obse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haemophilia
Main Authors: Fukutake, Katsuyuki, Taki, Masashi, Matsushita, Tadashi, Sakai, Michio, Takata, Ami, Yamaguchi, Hiromi, Karumori, Toshiyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852692/
https://ncbi.nlm.nih.gov/pubmed/31168882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13783
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados